未登录

C

Christian M Gill

Hartford Hospital

H指数:15

被引数:893

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Assessment of Meropenem Stability in Meropenem Admixtures Using 2 g Vials and Normal Saline Prepared Using addEASE® Connectors

使用addEASE®连接器，通过2 g安瓿瓶和生理盐水评估美罗培南在美罗培南混合物中的稳定性

Hospital Pharmacy

IF0.7

2025-10-010

PRE

In vitro persistence of clinical methicillin-resistant Staphylococcus aureus isolates from bone and joint infections after exposure to daptomycin, telavancin, and vancomycin

MICROBIOLOGY SPECTRUM

IF3.8

2025-10-010

PRE

Comparison of the in vivo efficacy and resistance development potential between cefiderocol and ceftolozane/tazobactam human simulated exposures against Pseudomonas aeruginosa in 72-hour murine thigh infection model

INFECTIOUS DISEASES

IF2.3

2025-03-010

PRE

Dose optimization of piperacillin/tazobactam, cefepime, and ceftazidime for carbapenem-resistant Pseudomonas aeruginosa isolates in Turkiye

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

IF3

2024-11-150

PRE

Differential frequency of persister cells in clinically derived isolates of Pseudomonas aeruginosa after exposure to cefiderocol and ceftolozane/tazobactam

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2024-10-240

PRE

Deciphering the Efficacy of β-Lactams in the Face of Metallo-β-Lactamase-Derived Resistance in Enterobacterales: Supraphysiologic Zinc in the Broth Is the Culprit

OPEN FORUM INFECTIOUS DISEASES

IF3.8

2024-04-231

OAAI

Assessing the impact of meropenem exposure on ceftolozane/tazobactam-resistance development in Pseudomonas aeruginosa using in vitro serial passage

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2024-04-022

PRE

Validation of a Stenotrophomonas maltophilia bloodstream infection prediction score in the hematologic malignancy population

ANNALS OF HEMATOLOGY

IF2.4

2024-03-081

OAAI

Assessing the in vivo impact of novel β-lactamase inhibitors on the efficacy of their partner β-lactams against serine carbapenemase-producing Pseudomonas aeruginosa using human-simulated exposures

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2024-01-131

PRE

In vitro activity of cefiderocol against a global collection of carbapenem-resistant Pseudomonas aeruginosa with a high level of carbapenemase diversity

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2023-12-2812

OAAI

In vitro synergy of the combination of sulbactam-durlobactam and cefepime at clinically relevant concentrations against A. baumannii, P. aeruginosa and Enterobacterales

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2023-10-1610

OAAI

Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2023-10-167

OAAI

Cefepime in vivo activity against carbapenem-resistant Enterobacterales that test as cefepime susceptible or susceptible-dose dependent in vitro: implications for clinical microbiology laboratory and clinicians

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2023-07-314

PRE

Assessing the in vivo efficacy of rational antibiotics and combinations against difficult-to-treat Pseudomonas aeruginosa producing GES β-lactamases

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2023-06-267

OAAI

In Vivo Pharmacodynamic Profile of EVER206, a Novel Polymyxin Antimicrobial, against Gram-Negative Bacteria in the Murine Thigh Infection Model

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

IF4.5

2023-05-170

OA

Directed carbapenemase testing is no longer just for Enterobacterales: cost, labor, and workflow assessment of expanding carbapenemase testing to carbapenem-resistant P. aeruginosa

EMERGING MICROBES & INFECTIONS

IF7.5

2023-03-013

OAAI

In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2023-02-1316

OAAI

Phenotypes, genotypes and breakpoints: an assessment of β-lactam/β-lactamase inhibitor combinations against OXA-48

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

IF3.6

2023-01-1012

PRE

Piperacillin/Tazobactam Dose Optimization in the Setting of Piperacillin/Tazobactam-susceptible, Carbapenem-resistant Pseudomonas aeruginosa: Time to Reconsider Susceptible Dose Dependent

CLINICAL THERAPEUTICS

IF3.6

2023-01-014

OAAI

Carbapenem-resistant Pseudomonas aeruginosa: an assessment of frequency of isolation from ICU versus non-ICU, phenotypic and genotypic profiles in a multinational population of hospitalized

ANTIMICROBIAL RESISTANCE AND INFECTION CONTROL

IF4.4

2022-11-3012

OAAI